Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis.
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mitoxantrone-related acute leukemia in MS: An open or closed book?
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
Genmab announces results of ofatumumab Phase II study in multiple sclerosis
A One Year Follow-Up Study of Natural Killer and Dendritic Cells Activities in Multiple Sclerosis Patients Receiving Glatiramer Acetate (GA).
Gordon Research Conference on Glia Biology: Functional Interactions among Glia & Neurons
US and EU regulatory authorities accept PLEGRIDY™ (peginterferon beta-1a) marketing applications for review
Genzyme provides update on U.S. LEMTRADA™ filing
Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
IFN-β inhibits T cells accumulation in the central nervous system by reducing the expression and activity of chemokines in experimental autoimmune encephalomyelitis.
Multiple Sclerosis and Pregnancy: Current Considerations.
One can prevent post-partum MS relapses by exclusive breast feeding: no.
Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Translating Fatigue to Human Performance.
Rituximab and multiple sclerosis.
New insights into signaling during myelination in zebrafish.
Interferon beta for secondary progressive multiple sclerosis.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Alemtuzumab benefits hard-to-treat MS patients
Breastfeeding and multiple sclerosis.
RTL therapy for multiple sclerosis: a Phase I clinical study.
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis.
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.

Pages